Trials / Unknown
UnknownNCT04538313
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
Early Clinical Trials on Evaluating the Tolerance, Safety and Efficacy of Autologous TILs in High-risk Recurrent Primary Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- CAR-T (Shanghai) Cell Biotechnology Co., Ltd. · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Early clinical trials on evaluating the tolerance, safety and efficacy of autologous TILs in high-risk recurrent primary hepatocellular carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tumor infiltrating lymphocyte | Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients. |
Timeline
- Start date
- 2020-08-26
- Primary completion
- 2022-10-31
- Completion
- 2022-10-31
- First posted
- 2020-09-04
- Last updated
- 2020-09-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04538313. Inclusion in this directory is not an endorsement.